CN107875382B - 用于治疗巨细胞病毒的组合物和方法 - Google Patents

用于治疗巨细胞病毒的组合物和方法 Download PDF

Info

Publication number
CN107875382B
CN107875382B CN201711042348.7A CN201711042348A CN107875382B CN 107875382 B CN107875382 B CN 107875382B CN 201711042348 A CN201711042348 A CN 201711042348A CN 107875382 B CN107875382 B CN 107875382B
Authority
CN
China
Prior art keywords
polypeptide
hcmv
protein
vlp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711042348.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107875382A (zh
Inventor
大卫·E·安德森
安妮-凯瑟琳·弗卢基格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Priority to CN201711042348.7A priority Critical patent/CN107875382B/zh
Publication of CN107875382A publication Critical patent/CN107875382A/zh
Application granted granted Critical
Publication of CN107875382B publication Critical patent/CN107875382B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
CN201711042348.7A 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法 Active CN107875382B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711042348.7A CN107875382B (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
CN201280066355.XA CN104271745A (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法
CN201711042348.7A CN107875382B (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280066355.XA Division CN104271745A (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法

Publications (2)

Publication Number Publication Date
CN107875382A CN107875382A (zh) 2018-04-06
CN107875382B true CN107875382B (zh) 2024-03-08

Family

ID=48290708

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280066355.XA Pending CN104271745A (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法
CN202010272504.4A Active CN111995664B (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法
CN201711042348.7A Active CN107875382B (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201280066355.XA Pending CN104271745A (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法
CN202010272504.4A Active CN111995664B (zh) 2011-11-11 2012-11-09 用于治疗巨细胞病毒的组合物和方法

Country Status (14)

Country Link
US (3) US9777043B2 (https=)
EP (2) EP3854416A1 (https=)
JP (2) JP6232544B2 (https=)
KR (2) KR102301463B1 (https=)
CN (3) CN104271745A (https=)
AU (3) AU2012335277B2 (https=)
BR (2) BR112014011229B1 (https=)
CA (2) CA2889659C (https=)
DK (1) DK2776567T3 (https=)
ES (1) ES2874233T3 (https=)
MX (2) MX353189B (https=)
PT (1) PT2776567T (https=)
RU (2) RU2019139064A (https=)
WO (1) WO2013068847A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330368B1 (en) 2009-06-18 2021-07-21 Kiyatec Inc. Bioreactor system
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA2889659C (en) 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP3613431B1 (en) * 2012-03-27 2023-01-11 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2885145A1 (en) * 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) * 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
EP3528821A4 (en) * 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019209632A1 (en) * 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
CN112638411B (zh) 2018-05-04 2025-03-04 斯拜生物技术有限公司 疫苗组合物
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
BR112021024157A2 (pt) * 2019-05-31 2022-04-26 Variation Biotechnologies Inc Composições imunoterapêuticas para tratamento de glioblastoma multiforme
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
EP4719470A1 (en) * 2023-06-02 2026-04-08 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440730B1 (en) * 1998-11-26 2002-08-27 Heinrich-Pette-Institut Retroviral hybrid vectors pseudotyped with LCMV
WO2010128338A2 (en) * 2009-05-08 2010-11-11 Henderson Morley Plc Vaccines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
DE68929478T2 (de) 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
EP1222281B1 (en) * 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
DK2311848T3 (da) 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
DE602004021260D1 (de) 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
WO2009120883A2 (en) * 2008-03-26 2009-10-01 Life Technologies Corporation Virus-like particle mediated cellular delivery
CA2889659C (en) 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
JP6679484B2 (ja) 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440730B1 (en) * 1998-11-26 2002-08-27 Heinrich-Pette-Institut Retroviral hybrid vectors pseudotyped with LCMV
WO2010128338A2 (en) * 2009-05-08 2010-11-11 Henderson Morley Plc Vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A Prime-Boost Strategy Using Virus-Like Particles Pseudotyped for HCV Proteins Triggers Broadly Neutralizing Antibodies in Macaques";Pierre Garrone等;《Science translational medicine》;20110803;第3卷(第94期);摘要，第1页左栏第2段至第6页右栏第3段 *
"Development of a cytomegalovirus vaccine lessons from recent clinical trials";Eva Gonczol等;《Expert opinion on biological therapy》;20010501;第1卷(第3期);摘要，第402页右栏第2段至409页右栏第2段 *
"GenBank：ACM48044.1";Bradley,A.J.等;《GenBank》;20090917;LOCUS、DEFINITION、FEATURE、ORIGIN *
"GenBank：ACM48061.1";Bradley,A.J.等;《GenBank》;20090917;LOCUS、DEFINITION、FEATURE、ORIGIN *

Also Published As

Publication number Publication date
WO2013068847A3 (en) 2014-10-30
US20170349634A1 (en) 2017-12-07
CN104271745A (zh) 2015-01-07
BR122019027913B1 (pt) 2021-11-30
KR20190104644A (ko) 2019-09-10
MX387666B (es) 2025-03-18
MX353189B (es) 2018-01-05
EP2776567A4 (en) 2015-12-30
EP3854416A1 (en) 2021-07-28
AU2012335277A1 (en) 2014-06-12
PT2776567T (pt) 2021-05-25
JP2018023374A (ja) 2018-02-15
US9777043B2 (en) 2017-10-03
JP6232544B2 (ja) 2017-11-22
KR102340558B1 (ko) 2021-12-21
US11248026B2 (en) 2022-02-15
EP2776567B1 (en) 2021-01-20
JP2015505299A (ja) 2015-02-19
AU2018203538A1 (en) 2018-06-07
CN111995664B (zh) 2024-08-02
AU2020264275A1 (en) 2020-11-26
CN107875382A (zh) 2018-04-06
US20140308308A1 (en) 2014-10-16
CA2889659A1 (en) 2013-05-16
CN111995664A (zh) 2020-11-27
RU2737530C1 (ru) 2020-12-03
JP6657150B2 (ja) 2020-03-04
MX2014005653A (es) 2014-09-04
WO2013068847A2 (en) 2013-05-16
BR112014011229A2 (pt) 2017-05-09
DK2776567T3 (da) 2021-04-26
CA3166278A1 (en) 2013-05-16
AU2020264275B2 (en) 2023-12-14
ES2874233T3 (es) 2021-11-04
US12421283B2 (en) 2025-09-23
KR20140095556A (ko) 2014-08-01
AU2012335277B2 (en) 2018-06-14
EP2776567A2 (en) 2014-09-17
KR102301463B1 (ko) 2021-09-14
RU2019139064A (ru) 2020-01-27
US20230272013A1 (en) 2023-08-31
CA2889659C (en) 2023-03-14
BR112014011229B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
CN107875382B (zh) 用于治疗巨细胞病毒的组合物和方法
BE1024516B1 (fr) Antigenes du cytomegalovirus
US11253587B2 (en) Vaccine compositions for the treatment of coronavirus
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
WO2025106738A1 (en) Sars-cov-2 immunogenic compositions
US20240350619A1 (en) Vaccines and compositions based on sars-cov-2 s protein
CN112512569A (zh) 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
WO2025106754A1 (en) Coronavirus vaccine
US20220233682A1 (en) Vaccine compositions for the treatment of coronavirus
WO2023239265A1 (ru) Гибридный ген для получения рекомбинантного rbd-антигена
CN116457011A (zh) 用于治疗冠状病毒的疫苗组合物
WO2015128731A2 (en) Compositions and methods for treatment of hepatitis c

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20330905